In silico analysis approach for screening new agents for breast cancer inhibitors based on 1,5-benzothiazepine

Q4 Pharmacology, Toxicology and Pharmaceutics
N. Frimayanti, Marzieh Yaeghoobi, Hamid Namavar, Mashitoh Cindy Utari, Meiriza Djohari, Cindy Oktaviana Laia
{"title":"In silico analysis approach for screening new agents for breast cancer inhibitors based on 1,5-benzothiazepine","authors":"N. Frimayanti, Marzieh Yaeghoobi, Hamid Namavar, Mashitoh Cindy Utari, Meiriza Djohari, Cindy Oktaviana Laia","doi":"10.29090/psa.2022.05.22.001","DOIUrl":null,"url":null,"abstract":"Combination of similarity searching with docking and molecular dynamic simulations were performed. In this study, chalcone-based 1,5-benzothiazepine compound (i.e. MA9) was used as parent compound, since it exhibits potential enhancement and improvement of biological activity over doxorubicin (i.e. the common agent for cancer treatment). The main aim of this study was to explore a new potential inhibitor against breast cancer from a large database. To study this effect, several computational approaches were applied. Initially, seven compounds were observed according to the Euclidean distance and Tanimoto coefficient. Parent compound and all these seven compounds were docked into 1T46 protein active site. Docking results reported that ZINC4377306 and ZINC4377309 have exhibited binding free energy of -6.75 and -6.49 kcal/mol, respectively. In addition, they showed the binding interaction through hydrogen bond, van der Waals and other interactions with the notable residues around the active site. Both compounds were stable during the molecular dynamic simulation. Thus, ZINC4377306 and ZINC4377309 can be used as new potential agents against breast cancer as an early stage in drug discovery process.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"48 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Sciences Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29090/psa.2022.05.22.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Combination of similarity searching with docking and molecular dynamic simulations were performed. In this study, chalcone-based 1,5-benzothiazepine compound (i.e. MA9) was used as parent compound, since it exhibits potential enhancement and improvement of biological activity over doxorubicin (i.e. the common agent for cancer treatment). The main aim of this study was to explore a new potential inhibitor against breast cancer from a large database. To study this effect, several computational approaches were applied. Initially, seven compounds were observed according to the Euclidean distance and Tanimoto coefficient. Parent compound and all these seven compounds were docked into 1T46 protein active site. Docking results reported that ZINC4377306 and ZINC4377309 have exhibited binding free energy of -6.75 and -6.49 kcal/mol, respectively. In addition, they showed the binding interaction through hydrogen bond, van der Waals and other interactions with the notable residues around the active site. Both compounds were stable during the molecular dynamic simulation. Thus, ZINC4377306 and ZINC4377309 can be used as new potential agents against breast cancer as an early stage in drug discovery process.
基于1,5-苯并噻唑类药物的乳腺癌抑制剂新药筛选的计算机分析方法
将相似性搜索与对接和分子动力学模拟相结合。本研究以查尔酮为基础的1,5-苯并噻唑类化合物(即MA9)作为母体化合物,因为它比阿霉素(即癌症治疗的常用药物)具有潜在的增强和改善生物活性的能力。这项研究的主要目的是从一个大型数据库中探索一种新的潜在的乳腺癌抑制剂。为了研究这种效应,应用了几种计算方法。首先,根据欧几里得距离和谷本系数对7个化合物进行了观察。亲本化合物和这7种化合物均停靠在1T46蛋白的活性位点。对接结果表明,ZINC4377306和ZINC4377309的结合自由能分别为-6.75和-6.49 kcal/mol。此外,它们还显示了与活性位点周围显著残基通过氢键、范德华等相互作用的结合相互作用。在分子动力学模拟中,这两种化合物都是稳定的。因此,ZINC4377306和ZINC4377309可作为潜在的抗乳腺癌新药物,处于药物发现的早期阶段。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Sciences Asia
Pharmaceutical Sciences Asia Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
0.90
自引率
0.00%
发文量
59
期刊介绍: The Pharmaceutical Sciences Asia (PSA) journal is a double-blinded peer-reviewed journal in English published quarterly, by the Faculty of Pharmacy, Mahidol University, Thailand. The PSA journal is formerly known as Mahidol University Journal of Pharmaceutical Sciences and committed to the timely publication of innovative articles and reviews. This journal is available in both printed and electronic formats. The PSA journal aims at establishing a publishing house that is open to all. It aims to disseminate knowledge; provide a learned reference in the field; and establish channels of communication between academic and research expert, policy makers and executives in industry and investment institutions. The journal publishes research articles, review articles, and scientific commentaries on all aspects of the pharmaceutical sciences and multidisciplinary field in health professions and medicine. More specifically, the journal publishes research on all areas of pharmaceutical sciences and related disciplines: Clinical Pharmacy Drug Synthesis and Discovery Targeted-Drug Delivery Pharmaceutics Biopharmaceutical Sciences Phytopharmaceutical Sciences Pharmacology and Toxicology Pharmaceutical Chemistry Nutraceuticals and Functional Foods Natural Products Social, Economic, and Administrative Pharmacy Clinical Drug Evaluation and Drug Policy Making Antimicrobials, Resistance and Infection Control Pharmacokinetics and Pharmacodynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信